If you missed any part of CURE®’s Educated Patient® Breast Cancer Summit, take a look at this roundup of stories that highlight the expert insight and guidance that was shared throughout the day.
CURE®’s Educated Patient® Breast Cancer Summit is a half-day virtual event that brings together members of the breast cancer community to discuss the rapidly changing field of the disease, all to help patients who attend.
Experts from across the country presented on the various subsets of breast cancer, genomic and biomarker testing, targeted therapies, and more. If you missed it live, you can view the entire summit here, or read our conference coverage below:
In addition to maintaining or increasing the amount of exercise one gets, a diet that is high in vegetables, fruits, whole grains and legumes is crucial for patients with breast cancer, according to Dr. Amy Comander.
Dr. Neelima Vidula, of Massachusetts General Hospital and Harvard Medical School, discusses the potential that several novel therapies hold in treating metastatic breast cancer, including PARP inhibitors, immunotherapy and antibody drug conjugates.
Triple-negative breast cancer, which is found in 15%-20% of invasive breast cancers, is a challenge when it comes to treatment, but thanks to new drug approvals and therapy regimens, the treatment landscape has progressed in recent years, according to an expert.
Targeted therapies that attack cancer in a more precise way than traditional chemotherapy are being used more often in the field of breast cancer, but the solution in utilizing them lies within the patient-oncologist relationship, according to Dr. Dejan Juric of the Massachusetts General Hospital Cancer Center.
With more than 4 million breast cancer survivors in the U.S., survivorship care and understanding what happens to patients after surviving is of the utmost importance. Dr. Jeffery Peppercorn, of Massachusetts General Hospital Cancer Center, explains some side effects survivors may experience and treatments to help.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.